Week in Review | AstraZeneca's Wainua Missed in ATTR-CM: The Stabilizer Problem

Three hundred eighty-one events versus three hundred ninety-two — AstraZeneca and Ionis's Wainua (eplontersen) missed in ATTR-CM, and the Munich post-mortem points at background therapy, not the molecule. With roughly four in five patients on a stabilizer, the trial answered an add-on question it was never built to ask — while at the same congress Alnylam put up a prespecified HELIOS-B subgroup of vutrisiran by baseline tafamidis use (259 of 654 randomized and treated patients), published in the Journal of the American College of Cardiology. Also this week: FDA approved Eli Lilly's Mounjaro (tirzepatide) for cardiovascular risk reduction in type 2 diabetes on a head-to-head trial against Trulicity (dulaglutide); BioNTech and Genentech terminated a Phase 2 of autogene cevumeran in colorectal cancer on an overall survival imbalance; Novartis pushed pacibekitug toward an outcomes trial in chronic kidney disease; and Teva bid for BioXcel's dexmedetomidine film out of bankruptcy.

Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.